RT Journal Article
SR Electronic
T1 Estimating Heritability of Glycaemic Response to Metformin using Nationwide Electronic Health Records and Population-Sized Pedigree
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20173922
DO 10.1101/2020.08.24.20173922
A1 Iris N. Kalka
A1 Amir Gavrieli
A1 Smadar Shilo
A1 Hagai Rossman
A1 Nitzan Shalom Artzi
A1 Eran Segal
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.24.20173922.abstract
AB Variability of response to medication is a well known phenomenon, determined by both environmental and genetic factors. Understanding the heritable component of the response to medication is of great interest but challenging due to several reasons, including small study cohorts and computational limitations. Here, we studied the heritability of variation in the glycaemic response to metformin, first-line therapeutic agent for type 2 diabetes (T2D), by leveraging 17 years of electronic health records (EHR) data from Israel’s largest healthcare service provider, consisting of over five million patients of diverse ethnicities and socio-economic background. Our cohort consisted of 74,871 T2D patients treated with metformin, with an accumulated number of 1,358,776 HbA1C measurements and 323,260 metformin prescriptions. We estimated the explained variance of glycated hemoglobin (HbA1c%) reduction due to heritability by constructing a six-generation population-size pedigree from pedigree information linked to medical health records. Using a Linear Mixed Model-based framework, a common-practice method for heritability estimation, we calculated a heritability measure of h2 = 10.5% (95% CI, 3.5%-17.5%) for absolute reduction of HbA1c% after metformin treatment, which remained unchanged after adjusting for pre-treatment HbA1c%, and h2 = 12.2% (95% CI, 5.2%-19.3%) for proportional reduction in HbA1c%. To the best of our knowledge, our work is the first to estimate heritability of drug response using EHR data. We demonstrated that while response to metformin treatment has a heritable component, most of the variation is likely due to other factors, further motivating non-genetic analyses aimed at unraveling metformin’s mechanism of action.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clalit healthcare organization. Experiment protocol number 0195-17-COM2. Experiment topic: Disease prediction models using retrospective data and statistical analysis of electronic health records.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study originates from Clalit healthcare. Restrictions apply to the availability of these data and so are not publicly available. Due to restrictions, it can only be accessed through requests from the authors and/or the Clalit healthcare organization.